t-cell therapy (Astlym)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namet-cell therapy (Astlym)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsHypersensitivityAutoimmune DiseasesNeoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAstlym Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstlym Co Ltd
Active IndicationsN/A
Inactive IndicationsHypersensitivityAutoimmune DiseasesNeoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A